CNA Rapid Sepsis Dx

CNAD has conducted multiple studies on sepsis patient populations and the CNA Rapid Sepsis Dx assay can be used to diagnose the onset of the disease before symptoms appear with a high rate of accuracy.

  CNAD results compare extremely well compared to using blood cultures or other available molecular tests for detection of sepsis.

While all existing sepsis diagnosis methods work only once the first clinical symptoms have appeared, the data collected for the CNA Rapid Sepsis DX assay  indicate that the test can be used with an accuracy (both sensitivity and specificity) of over 85% two days before the first clinical symptoms appear, thus increasing sepsis survival rates considerably and improving the quality of life for sepsis survivors due to the possibility to treat them earlier.

CNA Rapid Sepsis Dx is positioned for use on high risk patient cohorts including cancer patients post abdominal surgery, while admitted to the ICU and when presenting to the Emergency Room.

The test uses standard and cost-effective Polymerase Chain Reaction (PCR) diagnostic equipment and PCR Standard Operating Procedures, which are well established in blood laboratories worldwide, thus easing customer adoption.

CNA Rapid Sepsis Dx is presently in final U.S. clinical trials to support FDA clearance.  We believe this test will have a profound positive impact on worldwide healthcare systems and patient outcomes.

Understanding Sepsis

Sepsis impacts the lives of >30M people annually and kills >6M patients globally per year. It is one of the most-costly challenges to the global healthcare systems. For many years, it was believed that pathogen invasion was responsible for the damage seen in sepsis. Today, sepsis is being redefined as a dysregulated host response to infection by bacteria, fungi or viruses.

The early diagnosis of sepsis, when coupled with early treatment, will reduce a hospital’s overall cost of treatment, will lead to improved compliance with insurance coding for reimbursement claims, and contribute to a reduction of sepsis impact to a hospital’s environment. But most importantly, it will make a world of a difference to patients, who can be treated earlier, thus increasing their chances of survival by more than 50-fold and reducing the risk of major lifelong impact from sepsis infections for sepsis survivors.

© 2020 CNA Diagnostics Inc.